Andy already answered your questions but I think his point of applying the science learned from the HIV effort to the kinds of cancers that the CAR-T folks are going after is really the big take away here. If we get good solid data from these HIV trials (especially 1401) that Sangamo can modify the genetics of T cells then we have an open door to do the same thing but for blood cancers and possibly tumorous cancers if combined with other therapies (see Ziopharm's IL-12 trials; ZIOP). If multiple doses results in much better engraftment then Sangamo could have a platform for cancer treatment that competes well with the CAR-T efforts.
Proof of IVPR feasibility plus a T-cell cancer platform would certainly get the attention of investors.
Patience...